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Abstract 
Background: Recently, evidence in support of the Cancer Stem Cell (CSC) hypothesis 
has been accumulating. On the other hand, it has been reported that the expression of 
aldehyde dehydrogenase-1 (ALDH1) in primary breast cancer is a powerful predictor of 
a poor clinical outcome, and that breast cancer stem cells express ALDH1. According to 
the CSC hypothesis, development of metastases requires the dissemination of CSC that 
may remain dormant and be reactivated to cause tumor recurrence. In this study, we 
investigated whether the detection of CSC in axillary lymph node metastases (ALNM) 
might be a significant prognostic factor in patients with breast cancer. Patients and 
Methods: From 1998 to 2006, 40 primary breast cancer patients with ALNM, the 
number of metastatic nodes varying in number from 1 to 3, underwent surgery at 
Okayama University; of these, 15 patients developed tumor recurrence. We 
retrospectively evaluated the common clinicopathological features and the expressions 
of ER, HER2, ALDH1 and Ki67 in both the primary lesions and the ALNM, and 
analyzed the correlations between the expressions of these biological markers and the 
disease-free survival (DFS). Results: Expression of ALDH1 in the ALNM was 
significantly associated with the DFS (p=0.037). Conclusion: Evaluation of biomarkers’ 
expression in ALNM could be useful for prognosis in breast cancer patients with 1-3 
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metastatic lymph nodes. 
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Introduction 
While the CSC hypothesis was first proposed almost 150 years ago, it is in recent years 
that the hypothesis has rapidly gained ground. Advances in stem cell biology and 
development of new animal models to measure self-renewal have contributed to this 
renewed recognition of this hypothesis [1]. Cancer stem cells were first documented in 
acute myeloid leukemia by taking advantage of the cell sorting technology using 
various surface markers [2]. Subsequently, the presence of CSC has been reported in 
solid tumors, including breast cancer, brain cancer, lung cancer, and colon cancer, as 
well [3-6]. In breast cancers, Al-Hajj et al. were the first to distinguish between 
tumorigenic cancer cells and non-tumorigenic cells by using the cell surface markers 
CD44 and CD24 [3]. They showed that following inoculation into mice, as few as 500 
tumor cells with the CD44+/CD24- phenotype were able to form tumors in NOD/SCID 
mice, whereas even when as many as 105 to 106 tumor cells with other CD44/CD24 
phenotypes were unable to form tumors. Subsequently, Ginestier et al. reported that 
aldehyde dehydrogenase 1 (ALDH1) may be a better marker of breast cancer stem cells 
based on the finding that fewer ALDH1-positive than CD44+/CD24- tumor cells were 
needed to form tumors in immunodeficient mice [7]. According to the CSC hypothesis, 
metastases require the dissemination of cancer stem cells that may remain dormant and 
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be reactivated to cause tumor recurrence. In contrast, dissemination of differentiated 
tumor cells produces only micrometastasis that do not progress [1]. In breast cancers, 
metastasis often first appears in the axillary lymph nodes. Hence, it may be crucial 
importance to detect the presence of CSC in the axillary lymph nodes [8]. Axillary 
lymph node metastases are considered as the most important of prognostic factors in 
breast cancer patients, and the number of metastatic lymph nodes as the most powerful 
guide to selection of the most appropriate strategy for adjuvant therapy. When the 
number of ALNM was over 3, the risk of recurrence was considered to be high and 
adjuvant chemotherapy was considered to be necessary. The patients without ALNM 
were regarded as being at a low risk for recurrence and to therefore not need intensive 
adjuvant therapy. On the other hand, there has been much debate about the appropriate 
treatment for breast cancers with 1-3 lymph node metastases, because of the lack of 
definitive evidence [9].  
Recently, evaluation of biomarkers to assess the responses to particular breast cancer 
therapeutic strategies has received much attention. Under the present situation, the 
selection of therapeutic drugs for recurrent breast cancers are based only on the 
biomarker expression profile in the primary lesion evaluated at the time of the initial 
operation for the primary tumor. However, discordance of biomarker expression 
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between primary and distant metastatic tumors has been increasingly reported. 
In this study, we investigated the presence of cancer stem cells in ALMN, especially 
when the number of metastatic lymph nodes was under 4, might be a significant 
clinicopathological prognostic factor in patients with breast cancer, and the concordance 
of biological features between the breast tumors and the ALNM.  
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Materials and Methods 
Patients and sample studied 
Tumor tissue samples from the primary lesions and axillary lymph node metastases 
(ALNM) were obtained from 40 primary breast cancer patients who were primarily 
treated by surgery between 1998 and 2006 at Okayama University Hospital (OUH). 
Curative surgery, namely, total or partial mastectomy with axillary dissection was 
performed in all patients, and all patients had less than 3 metastatic lymph nodes in the 
axilla. After the surgery, the premenopausal patients with estrogen receptor-positive 
tumors were administered a selective estrogen receptor modulator (SERM) and 
luteinizing hormone-releasing hormone (LH-RH) agonist, and the postmenopausal 
patients were administered an aromatase inhibitor (AI) for five years. ER negative 
and/or histological grade 3 and/or >pT2 patients were administered adjuvant 
chemotherapy (AC or AC followed by Paclitaxel). Patients who underwent partial 
mastectomy were also administered radiation therapy for the residual breast tissue. After 
the adjuvant therapy, all the patients were periodically followed up at our hospital. 
Recurrences were diagnosed by radiological and pathological examination. 
Tumor tissues obtained at surgery were fixed in 10% buffered formalin and embedded 
in paraffin. The ALMN which had the largest metastases were examined. A routine 
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histological examination was performed in sections stained with hematoxylin-eosin 
(H-E). We retrospectively evaluated the common clinicopathological features and the 
status of expression of ER, HER2, ALDH1 and Ki67 in both the primary lesion and the 
ALNM, and analyzed the discordance rate between the two for each marker. 
Furthermore, we evaluated the correlation between the expression status of these 
biological markers and the disease-free survival (DFS).  
Histological grade, ER and HER-2 
The histological grade was determined using the Scarff-Bloom-Richardson grading 
system [10]. ER expression (Ventana Japan) was defined as positive when ≥10% of the 
tumor cells showed positive immunohistochemical staining. HER-2 was detected by 
immunohistochemical staining using the HercepTest kit (DAKO Japan). In this study, 
we considered the specimen to be HER-2 positive when more than 30% of the cells 
showed positive immunohistochemical staining.  
Immunohistochemical staining for ALDH1 and Ki-67  
Immunohistochemistry was performed on formalin-fixed paraffin sections (4 μm) of 
tumor tissues with the BOND TM automated immunostainer (Leica Microsystems). The 
protocol was in accordance with IHCFP H1 (30). The antibodies and dilutions used 
were ALDH1 (BD Biosciences) at 1:200 dilution, and Ki-67 (DAKO Japan) at 1:250 
 9
dilution. Imaging analysis of the breast tumors for ALDH1 expression was performed in 
one selected area (400× high-power field) per case. That of the ALNM was performed 
in 3-7 randomly selected areas (400× high-power field) per case. We calculated the 
percentage of ALDH1-positive cells and divided the intensity of the 
immunohistochemical staining for ALDH1 into positive (more than 5% tumor cells 
showing positive staining).  In the ALNM, Ki-67 expression was analyzed in 3-5 
selected areas (400× high-power field) per case. Ki-67 expression was considered to be 
positive when ≥20% of the cancer cells showed positive staining [11]. 
Statistical analyses 
The SAS software JMP 7.0.2 was used for all the statistical analyses. Regression 
analysis was used for analyzing the correlations in the expressions of the biomarkers 
between the primary tumors and the ALNM. Associations between the ALDH1 
expression status and the clinicopathological parameters were evaluated by the 
Chi-square test. Agreement for ALDH1 expression between the primary tumors and the 
ALNM was assessed by Cohen’s kappa coefficient. The log-rank test was used for 
comparison of the survival curves and the Cox proportional hazards model was used for 
the univariate and multivariate analysis. Statistical significance was assumed at P < 
0.05. 
 10
Results 
Patient characteristics 
The median age of the patients was 53 years (range, 28- 78 years). The median time on 
study with follow-up was 46 months (range, 6-143 months).Of the total, 15 (24%) 
patients were over 50 years old, and 25 (76%) were under 51 years old. The diagnosis in 
all patients was invasive carcinoma with ALNM, classified as N1 based on the seventh 
edition of the TNM classification. Out of the 40 patients, 32 (80%) were ER-positive 
and 8 (20%) were ER-negative, 9 (22.5%) patients were HER2-positive and 31 (77.5%) 
were HER2-negative, 11 (27.5%) patients were histological grade 1, 16 (40%) patients 
were histological grade 2 and 13 (32.5%) patients were histological grade 3, 16 (40%) 
patients had some recurrences (bone 7(18%), liver 4(10%), brain 1(3%), breast 2(5%), 
lung 2(5%), skin 1(3%), lymph nodes 6(15%)), 6(15%) patients died of cancer (breast 
cancer 5(12.5%), other cancer 1(2.5%)), 13 (32.5%) patients received adjuvant 
chemotherapy (anthracycline 10(25%), taxane 7(18%), anthracycline+taxane 7(18%) 
and cyclophosphamide+methotrexate+5-fluorouracil (CMF) 3(8%)), 22 patients 
received endocrine therapies (SERM 9(28%) and AI 15(38%)), and 7(17.5%) patients 
received no adjuvant treatment (Table 1).  
ER, HER2, Ki67 and ALDH1 expression status in the breast tumors and ALNM. 
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Of the 40 breast tumors, 32 (80%) breast tumors were ER-positive and 8 (20%) were 
ER-negative; 28 (70%) ALNM were ER-positive and 12 (30%) were ER- negative, 9 
(22.5%) breast tumors were HER2-positive and 31 (77.5%) were HER2-negativ; 10 
(25%) ALNM were HER2-positive and 30 (75%) were HER2-negative, 30 (75%) breast 
tumors were Ki67-positive and 10 (25%) were Ki67-negative; 31 (77.5%) ALNM were 
Ki67-positive and 9 (22.5%) were Ki67-negative, 7 patients (17.5%) were 
ALDH1-positive and 33 patients (82.5%) were ALDH1-negative; 10 patients (25%) 
were ALDH1-positive and 30 patients (75%) were ALDH1-negative (Table 2). The 
results of immunohistochemical staining for ALDH1 in the breast tumor and in the 
ALNM are shown in Figure 1 and Figure 2.  
Relationship between ALDH1-positive expression in the breast tumors and the 
clinicopathological parameters 
The ALDH1-positive breast tumors were significantly more likely to be ER-negative in 
the ALNM (p=0.012) and to be Ki67-positive in the primary tumor (p=0.031). No 
significant association was observed between ALDH1 positivity in the primary tumor 
and the histological grade, age of the patient, size of the primary tumor, lymph node 
status, ER expression in the primary tumor, HER2 expression in the primary tumor, 
HER2 expression in the ALNM, or Ki67 expression in the ALNM. These 
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ALDH1-positive ALNM were significantly more likely to depend on high histological 
grade (p=0.002), ER-negative in the ALNM (p=0.012) and Ki67-positive in the ALNM 
(0.002). No significant association was observed between ALDH1 positivity in the 
ALNM and the tumor size, HER2 expression in the primary tumor, HER2 expression in 
the ALNM, Ki67 expression in the primary tumor, or Ki67 expression in the ALNM 
(Table 2). 
Concordance rate of ER, HER2, Ki67 and ALDH1 expressions between the breast 
tumors and the ALNM 
The concordance rates of ER, HER2, Ki67 and ALDH1 expression between the breast 
tumors and the ALNM were 87.5%, 82.5%, 77.5% and 57.5%, respectively (Table 3). 
In order to show the associations for ALDH1-positive cancer cells between primary 
tumor and ALNM, we calculated Cohen’s kappa coefficient. When a cutoff point 
between high and low ALDH1 expression level was set at 5%, they showed moderate 
agreement (κ=0.481). 
Relationship between various biological factors and the patient prognosis (DFS) 
The associations of various biological factors, such as the ALDH1 (in the primary 
tumor and ALNM), Ki-67 (in the primary tumor and the ALNM), ER (in the primary 
tumor and the ALNM) expression status, age, histological grade, HER-2 expression 
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status (in the primary tumor and the ALNM) and the tumor size with the DFS were also 
studied. The ALDH1-positive ALNM group showed a poorer outcome in terms of the 
DFS (p=0.148; primary tumor, Figure 3a, p=0.037; ALNM, Figure 3b). Univariate 
analysis showed a significant association between ER expression in the ALNM 
(p=0.047) and histological grade of differentiation of the tumor (p=0.04) with the DFS, 
and ALDH1 expression in the ALNM was likely to be poor clinical outcome (p=0.055). 
Multivariate analysis showed no significant association between any of the variables 
and the DFS (Table 4). Further, we could not recognize any statistically significant 
association between these various biological factors and the overall survival (data not 
shown). 
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Discussions 
Abraham et al. performed immunohistochemical studies of CD44+/CD24- tumor cells 
in human breast cancer and reported that breast tumors containing a high proportion of 
CD44+/CD24- cells were more frequently associated with the development of distant 
metastases, although no association with the event-free or overall survival was shown 
[12]. Mylone et al. reported that the prevalence of CD44+CD24- exerted no significant 
impact on the patients’ prognosis, although a tendency towards increase of the 
disease-free survival was noted, because these cell populations might not originate from 
normal adult stem cells but from a transit cell. Moreover, the same authors reported that 
tumor cells with the CD44-CD24+ phenotype seemed to identify patients with worse 
disease-free and overall survivals among patients with tumors showing 
intermediate-grade differentiation [13]. Their results were supported by Baumann et al. 
who showed that with CD24 expression, breast cancer cells acquire enhanced ability for 
spread, movement and invasion, which facilitate the development of metastasis [14]. 
Ginestier et al. documented that immunohistochemically identified tumor ALDH1 
expression was associated with a poor prognosis in breast cancer patients [7]. ALDH1 
in cancer stem cells may be closely involved in stem cell differentiation by regulating 
the conversion of retinoic acid to oxidizing retinol [15]. Consequently, we thought that 
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immunohistochemically demonstrated CD44+CD24- cells may not have reliable 
prognostic significance. There have been no reports of the evaluation of ALDH1 
expression in ALNM. Thus, we investigated the biological markers of breast tumors and 
ALNM. Our result was that the expression of ALDH1 in ALNM was significantly 
associated with a shorter DFS. This result indicates that breast cancer patients with 1-3 
lymph node metastases, expression of ALDH1 in ALNM, would be tend to have earlier 
relapse. In this study, we examined the findings in immunohistochemically stained 
slides of both the breast tumors and ALNM in comparison with those in the 
H&E-stained slides. It has been reported previously that ALDH1 is expressed in both 
normal and cancerous mammary epithelial cells [7]. In this study also, we observed 
ALDH1-positive cells in normal mammary tissues, and excluded these cells from the 
present evaluation morphologically. Furthermore, quite a few macrophages exist in 
lymph nodes, and it has been reported that macrophages also show ALDH1 expression 
[16]. Therefore, we paid careful attention to excluding macrophages morphologically, 
especially in the ALNM. Ginestier et al. reported that ALDH1 positivity (using a cutoff 
value for ALDH1 of 5%) in the primary tumors was significantly associated with a poor 
overall survival (OS) [7]. However, the appropriate cutoff value for ALDH1 in ALNM 
or the correlations between ALDH1 expression in ALNM and the clinical outcome has 
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not yet been reported. In this study, we found no correlation between the expression of 
ALDH1 (>5%: positive) in the primary tumors and the clinical outcome (DFS; p=0.14). 
In regard to the correlation between the expression of ALDH1 in ALNM and the DFS, a 
significant association was found (p=0.037). Moreover we analyzed in lower cutoff 
value at 1%, because we thought it important whether CSC in ALNM was present, or 
not. There was significantly difference in DFS (data not shown).  It may be suggested 
that ALDH1-negative cells (not cancer stem cells) in ALNM do not survive or spread to 
other organs. Thus, the presence of ALDH1-negative cells in ALNM may indicate 
against a poor clinical outcome. On contrary, a few cancer stem cells may survive for a 
long period and expand, resulting in worsening of the patients’ prognosis. The 
association between the presence of ALDH1-positive cells and a poor clinical outcome 
in breast cancer may be attributable to the cancer stem cells being more likely to be 
transferred to other organs. On the other hand, observation of cancer stem cells in 
ALNM provides practical evidence for the presence/absence of dissemination. In other 
words, evaluation of the expression of ALDH1 in ALNM provides direct evidence of 
dissemination, in view of the CSC hypothesis. The results of this study lend support to 
this hypothesis.  
It was previously reported that ALDH1 expression was associated with features of 
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aggressive tumors such as high histological grade and ER negativity [17, 18], and that 
ALDEFLUOR positive cells exhibited features of basal breast cancers [19]. Our results 
consisted with previous reports, the ALDH1-positive breast tumors were significantly 
more likely to be ER-negative in the ALNM (p=0.012) and to be Ki67-positive in the 
primary tumor (p=0.031). These ALDH1-positive ALNM were significantly more likely 
to depend on high histological grade (p=0.002), ER-negative in the ALNM (p=0.012) 
and Ki67-positive in the ALNM (0.002).  
In regard to the concordance rate between primary tumors and the ALNM, some reports 
have indicated that while the concordance rate between primary tumors and the ALNM 
for ER was 81-96.6%, which for HER2 was 82.5-100% [20-23]. In this study, the 
concordance rates for ER and HER2 were 87.5% and 82.5% respectively; 4 patients 
were HER2-positive in the primary tumor and HER2-negative in the ALNM. The 
concordance rate for HER2 in this study seems to be slightly lower as compared with 
previous reports, perhaps because these patients may have received and shown good 
response to trastuzumab administered as postoperative adjuvant therapy. They referred 
that the genetic instability of breast cancer cells was likely to be a major cause for this 
diversity [24]. Moreover, we evaluated the expression of ER, ALDH1 and Ki67, a 
marker of cell proliferation, by immunohistochemistry. Our results revealed that the 
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concordance rate between the primary tumor and the ALNM was 87.5% for ER, 57.5% 
for ALDH1 and 77.5% for Ki67. These results also support the notion of possible 
discrepancies between the primary tumor and the ALNM.  
The low concordance rate of ALDH1 expression between the primary tumor and the 
ALNM suggests that ALDH1 expression plays an important role in the heterogeneity of 
breast cancers. When we assessed correlations of the expression between the breast 
tumors and the ALNM by Cohen's kappa coefficient, it showed moderate agreement 
（κ=0.481), indicating that they might have relatively similar statistical power for 
predict prognosis. However, a significant correlation between the expression of ALDH1 
and the DFS was found only in the ALNM (Odds ratio: 3.79, 95%CI: 1.37-12.1), which 
suggests that evaluation of ALDH1 in the ALNM is more likely to be useful for predict 
prognosis in breast cancer patients with ALNM compared to primary tumors.  
This study is relatively small and therefore, some true but weaker prognostic variables 
may not been detected as significant in this analysis. And also these protein levels from 
old samples might not represent the actual biological processes. Nevertheless we believe 
our findings are generalizable and are consistent with prognostic results observed in 
separate patient in previous publications [7, 25]. 
Thus, the results of this study indicate that evaluation of biomarker expression in the 
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ALNM may have clinical significance in terms of prognosis for breast cancer patients 
with ALNM (n=1-3). We need to conduct a prospectively study with a larger sample 
size to confirm the value and methods of evaluation of biomarker expression in ALNM. 
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Figure legends 
Figure 1: Immunohistochemical identification of ALDH1-positive tumor cells. The 
results of immunostaining of ALDH1 in breast cancer tissues: A. positive; B. negative 
Figure 2: Immunohistochemical identification of ALDH1-positive tumor cells. The 
results of immunostaining of ALDH1 in ALNM: A. positive; B. negative 
Figure 3a: Kaplan-Meier curve for disease free survival (DFS) according to ALDH1 
status in breast tumors 
Figure 3b: Kaplan-Meier curve for disease free survival (DFS) according to ALDH1 
status in ALNM 
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Table1. Patients Characteristics 
parameters   n   
age (years old): median 53 (28-78) 
operation total 13 (32.5%) 
 partial 27 (67.5%) 
Nodal status n=1 23 (57.5%) 
 n=2 7 (17.5%) 
 n=3 10 (25%) 
Histology IDC 37 (92.5%) 
 ILC 2 (5%) 
 other 1 (2.5%) 
Adjuvant therapy    
Chemotherapy:  13 (32.5%) 
 anthracycline 10 (25%) 
 taxane 7 (17.5%) 
 anthracycline+taxane 7 (17.5%) 
 CMF 3 (7.5%) 
Hormonal therapy:  22 (55%) 
 SERM (Tamoxifen) 9 (22.5%) 
 AI 15 (37.5%) 
None:  7 (17.5%) 
recurrence:  16 (40%) 
 bone 7 (17.5%) 
 liver 4 (10%) 
 brain 1 (2.5%) 
 lung 2 (5%) 
 breast 2 (5%) 
 lymph node 6 (15%) 
Death:  6 (15%) 
 breast cancer 5 (12.5%) 
  other 1 (2.5%) 
IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma 
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Table2. Relationship of ALDH1 positivity in the breast tumors with the clinicopathological 
parameters 
  ALDH1(breast tumor<5%)  ALDH1(ALNM<5%)  
 n positive, n(%) negative, n(%) p positive, n(%) negative, n(%) P 
        
All breast tumor 40 7 (17.5) 33 (82.5)  - -  
Lymph node 40 - -  10 (25) 30 (75)  
age    N.S.   N.S. 
50≦ 15 2(13) 13(87)  6 (40) 9 (60)  
50> 25 5(20) 20(80)  4 (16) 21 (84)  
Histological grade    N.S.   0.02 
1 11 0(0) 11(100)  0 (0) 11 (100)  
2 16 3(19) 13(81)  5 (31) 11 (69)  
3 13 4(31) 9(69)  5 (38) 8 (62)  
Tumor size    N.S.   N.S. 
2cm< 11 0 (0) 11 (100)  3 (27) 8 (73)  
2cm≧ 29 7 (24) 22 (76)  7 (24) 22 (76)  
Nodal status    N.S.   N.S. 
n=1 23 6 (26) 17 (74)  4 (17) 19 (83)  
n=2 7 0 (0) 7 (100)  3 (43) 4 (57)  
n=3 10 1 (10) 9 (90)  3 (30) 7 (70)  
ER        
breast tumor    N.S.   N.S. 
+ 32 5(16) 27(84)  6 (19) 26 (81)  
- 8 2(25) 6(75)  4 (50) 4 (50)  
ALNM    0.012   0.002 
+ 28 2(7) 26(93)  3 (11) 25 (89)  
- 12 5(42) 7(58)  7 (58) 5 (42)  
HER2        
breast tumor    N.S.   N.S. 
+ 9 2(22) 7(78)  3 (33) 6 (67)  
- 31 5(16) 26(84)  7 (23) 24 (77)  
ALNM    N.S.   N.S. 
+ 10 2(20) 8(80)  3 (30) 7 (70)  
- 30 5(17) 25(83)  7 (23) 23 (77)  
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Ki67        
breast tumor    0.031   N.S. 
20< 30 3 (10) 27 (90)  7 (23) 23 (77)  
20≧ 10 4 (40) 6 (60)  3 (30) 7 (70)  
ALNM    N.S.   0.002 
20< 31 5 (16) 26 (84)  6 (19) 25 (81)  
20≧ 9 2 (22) 7 (78)  4 (44) 5 (56)  
* Chi-square test  N.S.= not significant 
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Table3. Concordance rate of the biomarker expressions between the primary tumors and the ALNM  
 
 
  ER 
  (primary/metastatic tumor) (n=40) 
  +/+  +/-  -/+  -/- 
No. of patients 32 5 0 3 
% 80 12.5 0 7.5 
Concordance rate (%) 87.5 
     
  HER2 
  (primary/metastatic tumor) (n=40) 
  +/+  +/-  -/+  -/- 
No. of patients 6 3 4 27 
% 15 7.5 10 67.5 
Concordance rate (%) 82.5 
     
  Ki67 
  (primary/metastatic tumor) (n=40) 
  +/+  +/-  -/+  -/- 
No. of patients 5 5 4 26 
% 12.5 12.5 10 65 
Concordance rate (%) 77.5 
     
  ALDH1 
  (primary/metastatic tumor) (n=40) 
  +/+  +/-  -/+  -/- 
No. of patients 7 0 17 16 
% 17.5 0 42.5 40 
Concordance rate (%) 57.5 
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Table4. Univariate and multivariate analyses to identify predictors of the DFS 
  Univariate analysis Multivariate analysis 
    Odds ratio 95%C.I. p   Odds ratio 95%C.I. p  
        
ALDH1in the breast tumor (positive/ negative)  2.26 0.63-6.54 0.19    
ALDH1 in the ALNM (positive/ negative )  2.75 0.98-7.46 0.055    
Ki67 in the breast tumor ((positive/ negative )  1.89 0.64-5.08 0.24    
Ki67 in the ALNM ((positive/ negative )  2.07 0.65-5.71 0.2    
ER in the breast tumor (-/+)  2.85 0.13-1.13 0.076    
ER in the ALNM (-/+)  2.89 1.01-7.89 0.047 1.57 0.49-4.93 0.44 
Age (≦50 / >50)   1.24 0.46-3.64 0.68    
Histological grade (3/1, 2)  2.88 1.05-7.91 0.04 1.83 0.60-5.65 0.28 
HER2in the breast tumor (-/+)  1.7 0.54-4.70 0.34    
HER2 in the ALNM (-/+)  3.04 0.69-9.55 0.13    
Tumor size(>2cm / <2cm)  2.36 0.75-10.31 0.15    
 
 
